title: How do you treat patients with myalgia who take statins?
abstract: 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are safe and effective in lowering low-density lipoprotein cholesterol. As a result, they confer an all-cause mortality benefit across a wide range of patient groups. The utility of statins is limited by their adverse effects, including myalgias and rhabdomyolysis. These clinical events, plus other symptoms, constitute what is termed statin myopathy. This review summarizes current concepts of statin myopathy and presents strategies to minimize statin-associated myopathic complaints.
authors.affiliation: Division of Cardiology, Hartford Hospital, Hartford, CT 06102, USA.
authors.forename: Saadi A
authors.initials: SA
authors.lastname: Siddiqi
authors.forename: Paul D
authors.initials: PD
authors.lastname: Thompson
mesh_terms: D000465:Algorithms; D003402:Creatine Kinase / Q000032:analysis; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D009135:Muscular Diseases / Q000139:chemically induced*; D012307:Risk Factors; D014451:Ubiquinone / Q000031:analogs & derivatives / Q000627:therapeutic use; D014815:Vitamins / Q000627:therapeutic use
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014815:Vitamins; D014451:Ubiquinone; D003402:Creatine Kinase; C024989:coenzyme Q10